Traders should monitor for potential downward pressure on shares, especially if this selling follows weak recent performance or precedes an earnings release. The absence of buying and concentration of sales among senior executives may signal lack of near-term confidence at current valuations.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $33.75entry
- T+1 · 9mo ago +0.24%α +0.69% · $33.83
- T+5 · 9mo ago −5.93%α −4.80% · $31.75
- T+20 · 8mo ago −11.82%α −5.42% · $29.76
- T+60 · 6mo ago +1.23%α −6.52% · $34.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven executives at Teva Pharmaceutical exercised stock derivatives and several conducted open-market sales totaling approximately $2.13 million in the past week. The transactions are primarily non-cash exercises, but significant insider selling by multiple C-suite executives suggests profit-taking at current price levels.
Key Financial Metrics
Key Facts
- Multiple C-suite executives sold shares in open-market transactions on 2026-03-05.
- Total open-market sales amounted to $2,132,043 across five insiders.
- All sales occurred at $31.6684 per share, indicating coordinated timing.
- Selling executives include EVPs of Global Operations, Europe Commercial, U.S. Commercial, Interim Chief Legal Officer, and others.
- All sales were preceded by derivative exercises at $0 cost, suggesting option expirations or vesting events.
- No open-market purchases were reported, only sales and non-cash derivative exercises.
Financial Impact
$2.13 million in insider selling over 7 days
Risk Factors
- Insider selling could accelerate if stock remains above $31–32 range.
- Perception of negative sentiment may impact investor confidence, particularly if no offsetting corporate news emerges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-TEVA-1773087757920 |
Track record
61 reports on TEVA
6 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers